LH and FSH release
Kisspeptin-10 can stimulate pituitary gonadotropins through upstream GnRH signalling.
Explore the research →REPRODUCTIVE-HORMONE RESEARCH
Kisspeptin-10
Closely linked with reproductive hormones, Kisspeptin-10 is studied in fertility, hormone signalling and sexual-health research.
LH pulsatilityReproductive hormonesFertility research
Clear acute human hormonal effects; therapeutic role still investigationalHuman studies consistently show that kisspeptin-10 can stimulate gonadotropin release, but dosing can produce different responses by sex and endocrine state, and long-term clinical benefit is not established.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
What has kisspeptin-10 been shown to do in people?
Kisspeptin-10 attracts interest because it can switch on an important part of the body's reproductive hormone system. That direct connection with LH, FSH, fertility and testosterone has opened up research around reproductive health, hormone signalling and even sexual and emotional response.
Endogenous testosterone signalling
Men's-health interest focuses on stimulating the body's own reproductive axis.
Explore the research →Fertility
Kisspeptin signalling is central to ovulation and reproductive physiology.
Explore the research →Sexual-function research
Libido interest follows newer kisspeptin-54 trials and broader reproductive signalling.
Explore the research →THE SCIENCE BIT
Starting the reproductive-hormone conversation.
Kisspeptin-10 activates KISS1R, a receptor on neurons involved in releasing GnRH. GnRH then signals the pituitary to release LH and FSH, hormones that communicate with the ovaries and testes.
That makes kisspeptin an upstream regulator, rather than testosterone itself. Responses depend on sex, hormone state and how the signal is delivered.
See the studies & trials →- KISS1R
- Kisspeptin receptor
- GnRH
- The next hormone message
- LH / FSH
- Pituitary reproductive signals
How this connects to the research
Human mechanistic evidence is stronger than broad wellness claims.
FROM MOLECULE TO TISSUE
Where Kisspeptin-10 connects with the body
These are the tissues and biological systems behind the interest in Kisspeptin-10.
- Hypothalamus
- GnRH-regulating neurons.
- Pituitary
- LH and FSH release.
- Reproductive organs
- Downstream hormone responses.
The research behind the interest
LH and FSH release
Kisspeptin-10 can stimulate pituitary gonadotropins through upstream GnRH signalling.
Human bolus and infusion studies report rapid LH responses, with sex- and cycle-dependent differences.
Strong human mechanistic evidenceExplore the studies →Endogenous testosterone signalling
Men's-health interest focuses on stimulating the body's own reproductive axis.
Small proof-of-concept studies reported increased LH and testosterone during infusion.
Early human evidenceExplore the studies →Fertility
Fertility is one of the clearest areas of human research, including studies looking at egg maturation and hormone responses in assisted reproduction.
Human research explores hormone release and assisted-reproduction applications, but many studies use kisspeptin-54 or longer-acting agonists rather than kisspeptin-10.
Growing peptide-family evidenceExplore the studies →Sexual-function research
Libido interest follows newer kisspeptin-54 trials and broader reproductive signalling.
Those sexual-desire findings should not be automatically attributed to kisspeptin-10.
Related-peptide human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableKisspeptin-10 reproductive hormone release in men and women ↗
Healthy men and women across menstrual-cycle phases
Intravenous bolus
LH and FSH increased in healthy men and in women during the preovulatory phase.
Responses differed by sex and cycle phase, showing why context matters.
Kisspeptin-10 stimulates LH and increases pulse frequency in men ↗
Healthy men
IntravenousBolus or monitored infusionUp to 22.5 hours
Boluses from 0.01 to 3.0 mcg/kg produced dose-related LH responses; 1 mcg/kg raised mean LH from 4.1 to 12.4 IU/L at 30 minutes.
A 4 mcg/kg/hour infusion increased LH and testosterone, while 1.5 mcg/kg/hour increased LH pulse frequency in the short study setting.
Kisspeptin-10 in hypotestosteronaemic men with type 2 diabetes ↗
Five men with type 2 diabetes and low testosterone plus healthy comparators
Intravenous infusion · 4 mcg/kg/hourSingle monitored session11 hours
LH rose from 3.9 to 20.7 IU/L during infusion and testosterone increased in the study setting.
Five participants is far too small to establish a treatment for low testosterone or a chronic regimen.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
Multiple controlled physiology studies demonstrate acute hormone release in humans.
✓
Clinical efficacyLimited
2/5 evidence depth
Therapeutic fertility, hypogonadism or sexual-function benefits remain investigational.
◇
Safety evidenceDeveloping
3/5 evidence depth
Short infusion studies provide useful safety data; chronic self-administration is not well studied.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Extensive reproductive-axis research supports the mechanism.
HOW TO READ THESE SCORESDeveloping preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEKisspeptin-10Mechanism → measured response → clinical outcome
Controlled bolus and infusion studies show acute response
No established chronic treatment or self-use protocol
Subcutaneous equivalence, desensitisation and outcomes
Keep route, study setting and outcome together
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Kisspeptin-10
Community interest centres on fertility, libido and increasing endogenous testosterone. Acute human hormone responses are real, but longer-term outcomes and practical self-administration remain uncertain.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Reproductive hormone signalling
Interest includes stimulating LH and downstream reproductive hormones. People may be seeking an alternative to directly supplying a hormone, but a short-term endocrine response does not guarantee a sustained clinical benefit.
- What makes a report informative
- Measured hormones in a defined endocrine context.
- What can muddy the picture
- Baseline function and pulse pattern materially affect the response.
Fertility-related goals
Kisspeptin research attracts people interested in ovulation, fertility and the reproductive axis. A laboratory hormone rise, egg maturation and a successful pregnancy are distinct outcomes.
- What makes a report informative
- The exact fertility endpoint and specialist treatment setting.
- What can muddy the picture
- Results for a studied kisspeptin formulation cannot automatically transfer to another peptide or schedule.
Desire and sexual wellbeing
Human sexual-response research draws interest in libido and sexual experience. This goes beyond a simple more-testosterone story and needs attention to mood, relationships and the research population.
- What makes a report informative
- Desire, distress and meaningful sexual wellbeing.
- What can muddy the picture
- Brain-response or hormone changes are not the same as a reliable benefit in everyday life.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Increasing LH and testosterone
This is the best-supported biological effect in men.
Human findings & limits
Bolus and infusion studies show acute LH and testosterone responses.
Laboratory & animal context
Reproductive-axis biology strongly supports the mechanism.
What this means: A demonstrated acute hormonal effect, not yet an established long-term therapy.
Fertility support
Users discuss ovulation, sperm health and preserving reproductive-axis function.
Human findings & limits
Kisspeptin-family research is active, but direct kisspeptin-10 treatment outcomes are limited.
Laboratory & animal context
KISS1R signalling is essential to reproductive physiology.
What this means: Strong mechanism with investigational clinical application.
Libido and sexual wellbeing
Interest has grown after newer kisspeptin studies in low sexual desire.
Human findings & limits
Positive sexual-desire trials largely used kisspeptin-54, not necessarily kisspeptin-10.
Laboratory & animal context
Central reproductive and emotional pathways offer a rationale.
What this means: Related-peptide evidence should not be silently transferred to kisspeptin-10.
Pulse timing and desensitisation
Users often discuss intermittent dosing to preserve a pulsatile reproductive signal.
Human findings & limits
Acute KP-10 infusions can increase LH pulsatility, but no chronic subcutaneous schedule has established sustained benefit.
Laboratory & animal context
Continuous versus pulsatile exposure can produce different reproductive-axis effects.
What this means: A plausible concern, without a validated community cycle or break interval.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDAn intermittent community pattern beyond the IV evidence
This example reflects discussion of subcutaneous Kisspeptin-10. Published human physiology studies used measured IV boluses or monitored infusions with frequent hormone sampling.
1Week 1
50 mcg · 2–3 timesAnecdotal subcutaneous starting pattern
2Week 2
50–100 mcg · 2–3 timesOptional community-described step-up
3Weeks 3–4
Up to 200 mcg per useUpper end of recurring descriptions
4After course
Pause & reviewNo validated desensitisation-prevention interval
What people commonly discuss50–200 mcg per subcutaneous use, several times weekly for a short 2–4-week course, appears in community protocol summaries.
What remains unvalidatedSubcutaneous bioavailability, chronic endocrine outcomes, escalation, fertility benefit and the proposed break are not validated.
ROUTE & DELIVERYThe published numbers are intravenous and weight-based
Human studies tested 0.01–3.0 mcg/kg IV boluses and 1.5–4 mcg/kg/hour infusions. They do not establish an equivalent flat subcutaneous amount.
PROFESSIONAL SOURCE CONTEXT
Kisspeptin-10 LH study · free full paper ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Human kisspeptin-10 studies use tightly controlled bolus or infusion protocols; they do not establish a self-administered fertility or testosterone regimen.
PUBLISHED HUMAN RESEARCH
View source ↗Healthy-men dose-response and LH-pulse study ↗
Healthy men in monitored physiology experiments
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Healthy men in monitored physiology experiments. Route: Given into a vein (IV). The study lasted up to 22.5 hours. The figures below describe the research design, not a personal schedule.
| First amount studied | 0.01–3.0 micrograms per kilogram of body weight single doses given into a vein |
|---|---|
| Later or target amount | 1.5 or 4 micrograms per kilogram of body weight each hour continuous doses given into a vein |
| How often? | one monitored dose or given continuously under monitoring |
| How was it given? | Given into a vein (IV) |
| How long? | Up to 22.5 hours |
See the exact study wording +
Start / initial: 0.01–3.0 mcg/kg IV boluses
End / target: 1.5 or 4 mcg/kg/hour IV infusions
Frequency: Single bolus or continuous monitored infusion
Route: Intravenous
Study duration: Up to 22.5 hours
Source: George et al., 2011 ↗
These are acute endocrine research protocols with frequent blood sampling—not a self-administration schedule.
PUBLISHED HUMAN RESEARCH
View source ↗Hypotestosteronaemic men with type 2 diabetes ↗
Five men with type 2 diabetes and low testosterone
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Five men with type 2 diabetes and low testosterone. Route: Given into a vein (IV). The study lasted 11 hours. The figures below describe the research design, not a personal schedule.
| First amount studied | 4 micrograms per kilogram of body weight each hour |
|---|---|
| How often? | given continuously under monitoring |
| How was it given? | Given into a vein (IV) |
| How long? | 11 hours |
See the exact study wording +
Start / initial: 4 mcg/kg/hour
End / target: 4 mcg/kg/hour
Frequency: Continuous monitored infusion
Route: Intravenous
Study duration: 11 hours
Source: George et al., 2013 ↗
The very small proof-of-concept study cannot define a treatment dose, course or long-term benefit.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · extrapolated from acute IV physiologyWhat people commonly discuss
STARTING APPROACHES
Community descriptions often begin around 50–100 mcg subcutaneously, sometimes increasing toward 200 mcg. Human IV data do not validate that conversion.
DURATION / CYCLES
Intermittent use or short 2–4-week courses are discussed to limit continuous receptor stimulation.
MAINTENANCE DISCUSSION
No validated subcutaneous titration, maintenance or break schedule exists for fertility, testosterone or libido goals.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Monitored endocrine-study guide
Human research · specialist infusionHuman kisspeptin-10 experiments used weight-based exposure with endocrine monitoring. Infusion rates are not amounts per calendar reminder, and kisspeptin-54 is a different peptide. Record appointments or an existing specialist schedule rather than converting those studies into a fixed injection programme.
Form and route: Weight-based intravenous bolus or infusion
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Kisspeptin-10
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDKisspeptin-10
→
OFTEN EXPLORED WITHKisspeptin-10 + fertility treatment
Kisspeptin-10 + Specialist fertility care
→
OFTEN EXPLORED WITHKisspeptin-10 + testosterone-focused care
Kisspeptin-10 + Endocrine assessment
→
OFTEN EXPLORED WITHKisspeptin-10 + hCG
Kisspeptin-10 + Human chorionic gonadotropin
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
KKISSPEPTIN-10 IS USUALLY DISCUSSED AROUNDUpstream GnRH, LH and FSH activation
＋Acute hormone responses are well demonstrated, while durable fertility or testosterone outcomes are not established.
PTHE PAIRED APPROACH MAY ADDSpecialist fertility care or an endocrine assessment pathway
A measured diagnosis, sex, cycle phase and treatment goal are more important than adding a second hormone-active compound.
＋
OFTEN EXPLORED WITH
Explore →＋Kisspeptin-10 + fertility treatment
Kisspeptin-10 + Specialist fertility careWHY IT IS EXPLOREDResearch interest follows kisspeptin's upstream control of the reproductive axis.
Fertility protocols are specialist and may use different kisspeptin forms or agonists.OFTEN EXPLORED WITH
Explore →＋Kisspeptin-10 + testosterone-focused care
Kisspeptin-10 + Endocrine assessmentWHY IT IS EXPLOREDExplored as a way to stimulate endogenous LH and testosterone.
Small mechanistic studies do not establish an alternative to diagnosed-condition treatment.OFTEN EXPLORED WITH
Explore →Kisspeptin-10 + hCG
Kisspeptin-10 + Human chorionic gonadotropinWHY IT IS EXPLOREDCommunity discussion combines an upstream hypothalamic signal with direct LH-receptor stimulation.
No controlled human study establishes benefit, endocrine balance or a safe combined schedule.01Define the endocrine goal
Ovulation, spermatogenesis, libido and low testosterone are not interchangeable outcomes.
02Do not stack by pathway alone
hCG, GnRH analogues and sex hormones can alter the same axis in different ways.
03Use laboratory context
LH, FSH, testosterone or estradiol need timing and clinical interpretation, not isolated snapshots.
Safety context
SAFETY & UNCERTAINTY
Hormonal response depends on sex, timing and endocrine state
01ENCOURAGING CONTEXTAcute human endocrine effects are reproducible
Controlled studies show that Kisspeptin-10 can rapidly alter LH, FSH and downstream sex-hormone signalling.
02THE IMPORTANT BOUNDARYResponse depends on biological context
Sex, menstrual phase, baseline endocrine state and exposure pattern materially change the response.
03WHAT REMAINS UNKNOWNChronic self-administration
Subcutaneous equivalence, sustained fertility outcomes, desensitisation risk and long-term safety are not established.
What the current evidence saysKisspeptin-10 can alter LH, FSH and testosterone rapidly. Repeated exposure may change responsiveness, while effects in pregnancy, hormone-sensitive disease and unsupervised combinations require particular caution.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Manipulating the reproductive axis may affect ovulation, pregnancy planning and assisted-reproduction treatment.
Hormone-sensitive cancers, pituitary disease and unexplained reproductive symptoms change the risk assessment.
LH, FSH, testosterone and estradiol vary with timing and physiology and need clinical interpretation.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
9 sourcesSources used on this profile
Original publicationKisspeptin-10 reproductive hormone release in men and womenJournal / DOI ↗Bibliographic recordKisspeptin-10 reproductive hormone release in men and womenPubMed ↗Original publicationKisspeptin-10 stimulates LH and increases pulse frequency in menFree full paper ↗Original publicationKisspeptin-10 stimulates LH and increases pulse frequency in menJournal / DOI ↗Bibliographic recordKisspeptin-10 stimulates LH and increases pulse frequency in menPubMed ↗Original publicationKisspeptin-10 in hypotestosteronaemic men with type 2 diabetesJournal / DOI ↗Bibliographic recordKisspeptin-10 in hypotestosteronaemic men with type 2 diabetesPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Kisspeptin-10 is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.